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Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors  
Paul C Langley, PhD, Adjunct Professor, University of Minnesota 
 
Abstract 
Pricing by the manufacturers of the two PCSK9 inhibitors recently approved by the FDA, evolocumab and alirocumab, has led to an 
ongoing debate over the value of these interventions in clinical practice. In the US, the Institute for Clinical and Economic Review (ICER) 
has been in the forefront of those who have argued that, in the context of notional incremental willingness-to-pay thresholds, 
manufacturers should reduce drug prices substantially. This conclusion has been echoed in a number of other technology assessments, 
notably in assessments by the National Institute of Health and Care Excellence (NICE) in the UK. At the same time, other evaluations 
have reported favorably, arguing that at current US prices, the two products meet willingness-to-pay benchmarks. The purpose of this 
commentary is not to argue for or against current PCSK9 pricing policies but to point out that the case made for possible price 
adjustments rest upon technology assessments that fail to meet the standards of normal science. Modeled claims that are properly 
classified as pseudoscience. The claims made are non-evaluable. Formulary committees, rather than accepting these claims at face 
value, should step back and work with manufacturers to develop claims that are targeted, robust, evaluable and replicable in a 
timeframe where feedback on PCSK9 outcomes are meaningful to health system decision makers.  
 




The recent overview of the 22 commentaries on health 
technology assessment published in INNOVATIONS in pharmacy 
between July 2016 and February 2017 has emphasized the 
importance of distinguishing science from pseudoscience             
in published claims for product performance 1. These  
commentaries have made clear that constructing imaginary 
worlds to support hypothetical cost-effectiveness claims for 
new products puts to one side any commitment to the 
standards of normal science; an advocacy of intelligent design 
rather than natural selection. Rather than supporting modeled 
claims or hypotheses that are credible, evaluable and 
replicable, model builders ask health care decision makers to 
take their word for claims and recommendations based on the 
creation of imaginary worlds. These include the reference case 
mandated by the National Institute for Health and Care 
Excellence (NICE) in the UK and, most recently, version 4.0 of 
the guidelines released by the Canadian Agency for Drugs and 
Technologies in Health (CADTH) in March 2017 2 3. In the latter, 
it was made quite explicit that the guidelines are not intended 
to be judged by the standards of normal science. They are 
intended, in setting criteria for the construction of imaginary 
simulations to support cost-outcomes claims, to ‘inform’ health 
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Lifetime or long-term modeled claims for comparative product 
performance are, by definition, immune to failure. Health care 
systems have no idea whether the claims are right, if they are 
wrong, if they are misleading or even if they should be taken 
seriously. This dilemma applies  both to clinical claims, which 
are typically put forward as indirect comparisons from  network 
meta-analyses, which should be seen as hypotheses and not 
taken at face value, and to cost-outcomes claims. In the latter 
case the exemplars are the modeled, yet unevaluable, 
incremental-cost-effectiveness ratio (ICER) claims and the 
resulting unevaluable lifetime cost-per-quality adjusted life 
year (QALY) claims. These unevaluable claims, together with the 
application of probabilistic sensitivity analyses and cost-
effectiveness acceptability functions, are seen by professional 
associations such as the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) and the 
Academy of Managed Care Pharmacy (AMCP) as the gold 
standard in constructing models to support formulary 
submissions 4 5.   A situation which is reinforced by the 
willingness of leading health technology assessment journals to 
publish unevaluable modeled claims 6 7 8  The downside here, 
for those who subscribe to the scientific method, is that there 
is now an accepted role for imaginary constructs in health 
technology assessment; a belief that non-evaluable, lifetime 
comparative product claims are sufficient to support formulary 
decisions. This is a commitment to pseudoscience (a.k.a pure 
bunk) 9. This position, as emphasized in previous commentaries, 
flies in the face of the Royal Society motto (founded 1660; Royal 
Charter 1662): nullius in verba (take no man’s word for it) 10. The 
Royal society website notes that this is an ‘expression of the 
determination of Fellows to withstand the domination of 
authority and to verify all statements by an appeal to facts 
determined by experiment’ 11 . 
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The purpose of this commentary, given the accepted standards 
of normal science that have been for the in place for the last 
350 years, is to consider the status  of the various modeled 
claims put forward following the marketing approval in the US 
for the two PCSK9 inhibitors for reducing low-density 
lipoprotein cholesterol (LDL-C) levels: evolucumab and 
alirocumab  The  PCSK9 models considered are: (i) the ICER 
evidence review model 12; (ii) the Kazi et al revisiting of the ICER 
model 13; (iii) the Arrietta et al model 14; (iv) the Gandra et al 
model 15 ; (v) the Toth et al model ; (vi)16 the Jena et al social 
value model 17;  and (vii) the Shah et al comparative cost of 
treatment model 18. 
 
Models have also been developed in other countries, in 
particular the models developed by the respective 
manufacturers for submission to NICE, together with the 
models developed by the NICE evidence review group 19 20 21 22. 
These models are not considered in detail given the price 
differentials for the PCSK9 inhibitors between the UK (and 
European Union countries) and the US. Even so, the criticisms 
put forward here are relevant: none of the European models 
meet the standards of normal science. Although outside the 
scope of the present commentary, similar objections would 
apply to simulated incremental cost-utility claims for risk 
thresholds in the initiation of statin therapy in cardiovascular 
disease primary prevention 23.      
 
As well as considering the merits (or lack of them) in the various 
PSCK9 models and their recommendations (or otherwise) for 
price discounting, this commentary also reviews the case for 
willingness-to pay cost-per-QALY thresholds in 
recommendations for price discounting. This is of particular 
interest given the standards for QALY thresholds proposed by 
the American College of Cardiology/American Heart Association 
(ACC/AHA) Task Force on Performance Measures 24.  
 
The PCSK9 Modeled Claims 
It is important to recognize the limitations of the PCSK9  
evidence base. Without endorsing the construction of 
imaginary worlds, it is all too common for researchers to rush 
to judgement by constructing models where the key clinical 
inputs are limited to a few phase 2 and 3 trials, few (if any) of 
which would have been replicated in treatment practice. While 
the Food and Drug Administration (FDA) may be prepared to 
grant marketing approval on a limited evidence base, health 
care systems are, presumably, more concerned with replicated 
claims for effectiveness in treatment practice. As a result, the 
various PCSK9 models, given their time horizon, are forced to 
make assumptions to support lifetime or long-term claims for 
cardiovascular events between the statin standard of care and 
the introduction of PCSK9 intravenous therapy as an add-on to 
the statin standard of therapy; claimed model outcomes which 
will never be evaluated.  
 
A   recent systematic review of PCSK9 inhibitors points to the 
evidence gaps 25. The review considered results for 17 trials 
reported in 19 publications. Studies were graded on their 
limitations, directness, consistency and precision of the body of 
evidence: high strength, moderate strength, low strength or 
insufficient.  The review found low to high-strength evidence of 
moderate to large magnitude reductions in LDC-L when added 
to statin therapy in patients with familial forms of 
hypercholesterolemia and alone or added to ezetimibe in those 
intolerant of statins. Although there were no head-to-head 
studies, the lipid outcomes were fairly similar across trials, with 
evidence varying by target population and drug. However, the 
principal concern in the review was with the lack of evidence for 
long-term health outcomes. The authors concluded that the 
evidence is insufficient to draw conclusions because of the 
limited or absence of information on the long-term impact of 
large reductions in LDL-C. More to the point, perhaps, is the fact 
that the studies reviewed reported cardiovascular events as 
secondary outcomes; the studies were not powered to assess 
cardiovascular events.  
 
The ICER Model 
In November 2015, ICER released its final evidence report on 
the PCSK9 inhibitors for the treatment of high cholesterol 12. 
The goal of the report was to consider key issues that patients, 
providers, and payers face when making decisions about PCSK9 
inhibitor therapy, in particular to assess the comparative clinical 
effectiveness and comparative value of the two PCSK9 
inhibitors as a class for patients with elevated LDL-C. The 
incremental costs per outcomes achieved for the PCSK9 
inhibitors were evaluated using the CVD Policy Model of 
cardiovascular disease in the adult (over 35 years) US 
population. This is a simulated, discrete-state Markov model of 
coronary heart disease and stroke incidence, prevalence, 
mortality and costs. The model cycle is 12 months. The chronic 
cardiovascular disease categories are: coronary heart disease 
only, stroke only and combined prior coronary heart disease 
and prior stroke. Each state and event has an annual cost and 
quality of life adjustment, an annual probability of an event 
and/or transition to another state.  
 
ICER modeled the entire population of the US aged 35 to 74 
years in the year 2015. All direct and induced medical costs and 
relevant clinical outcomes were modeled over this time horizon 
until patients reached 95 years of age. Utilities and costs were 
assigned to each clinical event in the annual cycle and 
discounted at 3% annually. Deterministic and scenario-based 
sensitivity analyses were applied to capture input parameter 
uncertainty. Three target populations were considered: (i) 
familial hypercholesterolemia; (ii) pre-existing cardiovascular 
disease but unable to tolerate statins; and (iii) pre-existing 
cardiovascular disease despite receiving maximum tolerated 
statin therapy. Treatment strategies compared: (i) ezetimbe vs. 
PSK9 inhibitors for statin intolerant; and (ii) statin vs. ezetimbe 
vs. PSK9 inhibitors as base-case (ICER Table 9). The utilities in 
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the ICER model were derived from the Global Burden of Disease 
(GBD) disability weights study. Estimated utilities ranged from 
no history of cardiovascular disease (utility = 1) to history of MI 
and stroke (utility = 0.852). 
 
Outcomes were expressed as QALYs and ICERs in terms of both 
the PCSK9 inhibitors and ezetimibe relative to those 
tolerant/non-tolerant of statin therapy. The ICERs were 
calculated in terms of next most effective therapy. A 
willingness-to-pay threshold of $100,000 per QALY was 
assumed. The baseline model identified 605,000 patients with 
familial hypercholesterolemia which equated with 13.3 million 
years of treatment over 20 years. The risk of a major adverse 
cardiovascular event (MACE) in this population was estimated 
2.2 to 3.4 times higher than an age and gender-matched 
population without familial hypercholesterolemia. Compared 
to the control arm, treatment with ezetimibe was projected 
over the lifetime analytic horizon to avert  115,900 MACE and 
produce 250,000 additional QALYs. Adding a PCSK9 inhibitor 
would avert 324,200 MACE and yield 665,200 QALYs with an 
ICER of $230,000/QALY. This was driven by differences in drug 
costs between PCSK9 inhibitors ($14,350 per annum) vs. 
ezetimibe ($2,828 per annum). Weighted by the size of the 
three major subpopulations threshold prices at which the 
PCSK9 inhibitors were projected by ICER to be cost-effective 
were $3,166 ($50,000 threshold), $5,404 ($100,000 threshold) 
and $7,735 ($150,000 threshold).   
 
The Kazi Model 
The Kazi et al model follows the Markov structure of the ICER 
model (there is a shared authorship) 13. The model structure is 
again based on the CVD Policy Model of coronary heart disease 
and stroke incidence, mortality and costs for the population 35 
years or older. The model included the population to 74 years 
of age following them over the lifetime until death or survival 
to age 95 years. Two base case simulations were modeled: (i) 
heterozygous familial hypercholesterolemia with either a family 
history or no family history of premature coronary heart disease 
and (ii) preexisting atherosclerotic cardiovascular disease. The 
model included estimated direct medical costs, utilities were 
again from the Global Burden of Disease study, assigned to each 
clinical event in annual cycles and discounted at 3% per annum. 
Three treatment strategies were considered: (i) statin status 
quo; (ii) incremental ezetimibe; and (iii) incremental PCSK9 
inhibitors. Costs of PSCK9 inhibitors were for 2015 calculated as 
the mean of $14,600 for alirocumab and $14,100 for 
evolocumab.     
 
The addition of ezetimibe to statin therapy was estimated to 
avert 214,400 MACE and 628,500 additional QALYs. Treating 
the entire familial hypercholesterolemia population aged 35 to 
74 years (taking statins or statin intolerant) with PCSK9 
inhibitors was estimated to cost $323 billion more than treating 
with ezetimibe but with an offset of $17 billion for reduced 
cardiovascular care. The net result was an estimated $582,000 
per life year saved or $503,000 per QALY (vs. ezetimibe plus 
statin). The ICER of PCSK9 inhibitor to relative to status quo was 
$352,000 per QALY. At a $100,000 threshold, PCSK9 inhibitor 
prices would need to be $4,536 or less to be considered cost-
effective.  
 
The Arrieta Model 
The Arrieta et al model considers the cost-effectiveness of 
PCSK9 inhibitors, again comparing a statin plus PCSK9 inhibitor 
against statin standard-only therapy 14. Two perspectives were 
considered: (i) a health system perspective expressed as cost 
per QALY gained over standard therapy and (ii) a private payer 
perspective defined as return-on-investment and net present 
value over a patient lifespan. The question addressed was 
whether PCSK9 inhibitors add a positive net benefit to the 
health system and private payers. 
A Markov lifetime model was proposed that followed a 
hypothetical cohort of patients beginning at age 58 until death 
or age 100 years. Model parameters were cardiovascular event, 
mortality, treatment costs and health utility states. Baseline 
characteristics mimiced those of the evolocumab trial 
population. The key parameter in the model was the annual 
probability of a cardiovascular event over the lifetime of a 
patient. Projected annual probabilities for age 58 and beyond 
were estimated by applying one-year evolocumab relative risk 
reduction data under the assumption that the Framingham 
survival function is proportional to the unobserved evolocumab 
survival function; the relative risk reduction was estimated at 
49.2%. The model assumed a one-year cycle with patients 
transitioning between living a normal life under lipid lowering 
treatment or experiencing a cardiovascular event. After the 
event patients moved to a post-cardiovascular event stage 
characterized by a slow transition back to a normal life defined 
by quality of life and costs. Patients could remain in this state 
for up to five years, they could have a subsequent 
cardiovascular event or experience a cardiovascular related 
death. They could die of a non-cardiovascular event at any time. 
All costs and outcomes were discounted by 3% per annum. 
 
The cost-effectiveness analysis took a health system 
perspective with the ICER defined as the difference between 
the differences in therapy pathway costs less any avoided costs 
from cardiovascular events divided by difference in QALYs 
sourced from the EQ-5D index score for chronic conditions in 
the US. These were estimated at 0.79 at treatment and for the 
5 years post-event were assumed to be from a low of the 25% 
base score progressing non-linearly to the at treatment score. 
The payer perspective analysis was expressed in net present 
value terms as the avoided costs from treatment plus the 
insurance premium less the costs of treatment at a discount 
rate of 3% (i.e., the net present value divided by the cost of 
treatment). The model assumed a 12% annual turnover of plan 
membership.   
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At a PCSK9 price point of $14,000 per annum treatment costs 
were estimated to be $237,718 from a health system 
perspective and $73,137 from a payer perspective. Avoided 
costs due to reduced cardiovascular events were $5,800 from a 
health system perspective and $1,095 from a payer perspective. 
Cost per QALY was estimated to be $348,807. Life years gained 
was 0.88 and QALYs gained 0.66. Assuming a willingness to pay 
threshold of $100,000 per QALY, the PCSK9 inhibitoe would be 
cost-effective at annual cost of $4,250. At an annual cost of 
$14,000, PCSK9s are not financially viable for the private payer. 
The PCSK9s are only financially viable at a price of $600. 
 
The Gandra Model 
The Gandra et al lifetime Markov state-transition model 
focused on the cost-effectiveness of evolucumab added to the 
standard of care versus the standard of care alone in three 
populations with trial data available 15. These are: (i) patients 
with heterozygous familial hypercholesterolemia; (ii) patients 
with atherosclerotic cardiovascular disease, defined as ≥ 1 prior 
CVD event, without statin intolerance; and (iii) patients with 
atherosclerotic cardiovascular disease and statin intolerance. 
 
Health states in the model included no cardiovascular disease, 
established cardiovascular disease, acute coronary syndrome, 
post-acute coronary syndrome, ischemic stroke, post-ischemic 
stroke, heart failure, post hearty failure, coronary heart disease 
death, ischemic stroke death and von cardiovascular death. 
Patents could enter the model at no cardiovascular disease or 
at dedicated prior cardiovascular health states. Combined 
health states retained memory of prior events in the model. The 
predicted efficacy of evolocumab on reducing cardiovascular 
events were derived from the relative LDC-L reductions to week 
12 of the clinical program. Utilities for the no cardiovascular 
disease health states were estimated at 0.824 for the 
population ≥ 45 years of age  with utilities for other health 
states from a prior time trade-off study with 1 year evaluation 
of acute states and 10-year for chronic states. The WAC cost of 
evolocumab was $14,139. Discounts were not considered. 
 
The incremental costs of evolocumab added to standard of care 
alone in patients with heterozygous familial 
hypercholesterolemia, atherosclerotic cardiovascular disease 
without statin intolerance and patients with atherosclerotic 
cardiovascular disease and statin intolerance were $153,289, 
$158,307 and $136, 903 respectively for QALY gains of 2.02, 
1.12 and 1.36. These estimates yielded cost per QALY gained 
estimates of, again respectively, $75,863, $141,699 and $100, 
309. All ICERs met ACC/AHA intermediate value and WHO cost-
effectiveness thresholds. 
 
The Toth Model 
The Toth et al model extended the Gandra et al model to 
estimate real-world cardiovascular disease burden and value-
based price range of evolocumab in a US-context high-risk-
secondary prevention population 16. With the burden of 
cardiovascular disease evaluated from the UK Clinical Practice 
Research Datalink (CPRD), patients on high intensity statins 
were selected based on the FOURIER model eligibility criteria. 
Following the Gandra et al Markov state-transition model 
evolocumab plus the standard of care was compared to 
standard of care alone. Four treatment cohorts were 
considered: (i) high-risk prevalent atherosclerotic 
cardiovascular disease cohort; (ii) acute coronary syndrome 
cohort; (iii) ischemic stroke cohort; and (iv) heart failure cohort. 
Using the current annual cost of evolocumab (list price 
$14,100), the incremental lifetime costs  of adding evolocumab 
were $127,088 for patients with a baseline LDL-C ≥ 70mg/dL and 
$110,916 among those with a baseline LDL-C  ≥ 100mg/dL. The 
respective QALYs gained lifetime were 0.68 and 0.95 
respectively. The respective ICERs were $190,440 and 
$118,905. Under the deterministic variant of the model the 
value-based price of evolocumab was estimated to be $9,051 
for $100,000 per QALY, $11,935 for $150,000 per QALY and 
$14,819 for $200,000 per QALY. 
 
The Jena Model 
The Jena et al simulation model utilized projections of the 
population of the highest risk statin benefit groups (SBGs) with 
established atherosclerotic cardiovascular disease (SNG 1), LDL-
C levels ≥ 190mg/dL (SBG 2) and diabetes (SBG 3) to estimate 
the economic value of reducing the hyperlipidemia burden 
among those not achieving conventional LDL-C goals by 50% 
through introducing PCSK9 inhibitors 17. The economic value of 
averting CVD related death and MACE was estimated, first, by 
estimating the number of life-years gained from (i) averting a 
single death from clinical trial follow-up data and, because this 
might be an overstatement, (ii) life-years lost from ischemic 
heart disease from the US Burden of Disease Study and, second, 
from the value of reducing cardiovascular related 
hospitalizations. The value of life years gained and the savings 
from reduced hospitalizations were aggregated to generate an 
estimate of the value of reducing LDL-C by 50% and the value of 
PCSK9 inhibitors under each of the three uptake scenarios.  
 
Value-per-person-year for those in SBGs 1 and 2 were 
presented for five year intervals from 2015 to 2035. Key 
variables were (i) number of MACE and cardiovascular events 
avoided in each year; (ii) value from these averted events; and 
(iii) value per person per year comprising cost offsets and life 
years to give total social value. Two efficiency scenarios were 
considered: an LDL-C reduction by 59% in the conservative 
efficiency scenario with associated reductions in MACEs and 
cardiovascular deaths, and a 50% reduction in MACEs in the 
high efficiency scenario.  
 
The modeled estimates of net social value presented (benefits 
in excess of costs) suggested that this would be delivered by the 
PSCK9 inhibitors (at prices of $14,100 and $14,600 per year for 
evolocumab and alirocumab respectively) for average patients 
in SBGs 1 and 2 as long as the annual price was below $18,000 
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in a high efficiency scenario or $12,000 in a conservative 
efficiency scenario. As these estimates did not include any 
benefits from improvement in quality of life, the authors 
cautioned that they might be conservative. 
 
The Shah Model 
The Shah et al study tracked 103 patients on either alirocumab 
or evolocumab of whom 61 had a first cardiovascular event with 
total attributable costs of $8,904,361 18. The median 10 year risk 
of another event was calculated to be 13.1% with a total cost of 
$1,654,758. Assuming a 50% reduction in cardiovascular events 
on PCSK9 inhibitors in the 61 patients, $4,452,180 would have 
been saved in the past and future 10 year savings would have 
been $1,123,345. Net costs per patient per year were with 
PCSK9 inhibitors were estimated at $7,000 in the past and 
$12,459 in the future. The claim is that over a 10-year period 
the net cost of PCSK9 intervention is well below the $50,000 per 
year of life saved threshold. 
 
Accepting the PCSK9 Model Claims 
Apart from the fact that none of the models considered 
generated evaluable claims for the cost-effectiveness of PCSK9 
inhibitors, the recommendations for discounts required to meet 
willingness-to-pay thresholds showed  considerable variation. 
At a threshold of $100,000, the ICER et al and Kazi model et al 
yielded simulated cost-effective annual prices of $5,404 and 
$4,536 respectively with the Arrieta et al model recommending 
a price of $4,250 as a maximum 12 13 14. Against these results the 
Gandra et al model concluded there was no need for price 
adjustments for evolocumab given ACC/AHA intermediate 
willingness to pay and WHO cost-effectiveness thresholds while 
the Toth et al model variant yielded a price of $9,051 15 16. The 
Jena et al lipid control model, focusing on social value, 
concluded that discounting was unlikely once quality of life as a 
benefit entered the calculus 17. 
 
Obviously, differences in the specification of target populations 
for PSCK9 inhibitor therapy will impact model clams and go at 
least some way to reconciling differences between imaginary 
cost, QALY and ICER claims. In the case of the Gandra et al 
model, for example, the authors pointed out: (i) that the ICER 
model, in using the policy model, underestimated the impact of 
single risk-factor interventions; (ii) the underlying policy model 
was intended to model the entire US population not controlled 
on statins and not high-risk populations; (iii) the  policy model 
underestimated the incidence of chronic heart disease by 50%; 
and (iv) that the ICER model does not account for the elevated 
risk of cardiovascular events among heterozygous familial 
hypercholesterolemia and atherosclerotic cardiovascular 
disease patients 15. Similar comparisons could be made against 
other models. 
 
Beyond such differences are those attributable to the structure 
of the Markov model, the treatment pathway assumptions, the 
assumed acute and chronic disease states, modeled transition 
probabilities, direct medical cost assumptions and the choice of 
utility measure. Other  potential confounding factors could 
include, as noted in a recent review of the ICER report on 
targeted immune modulators (TIMs) in rheumatoid arthritis, 
the extent to which relevant comorbidities and their impact on 
model outcomes were accommodated, the treatment of 
adherence and persistence (or its absence), potential or 
anticipated price increases for the PCSK9 inhibitors and other 
resources captured in the model, and possible intervention of 
new therapies 26.  
 
It is, of course, always possible to compare the structure and 
assumptions of one modeled imaginary world against 
competitors, with the implicit claim that one model should be 
in the pole position for ‘belief in’ by a formulary committee. This 
has, it should be emphasized, nothing to do with uncertainty in 
input assumptions and probabilistic scenarios for cost-
effectiveness. It reflects, quite simply, a belief by the model 
builders that if there is a sufficient correspondence to their 
assumptions and descriptions of  perceived ‘future reality’ then 
their claims necessarily follow as ‘pertinent information’ for 
decision makers 27 . 
 
In addition, there is no reason why health care systems should 
adopt incremental cost-per-QALY thresholds as a decision 
metric or pay any attention to the construction of imaginary 
worlds to drive recommendations for price discounting. 
Certainly, in a fixed budget environment, the case can be made 
for incremental assessments on efficiency grounds, but it would 
also make sense for a health system to adopt a notional metric 
of a cost per life-year or a cost per QALY independent of 
efficiency considerations. Manufacturers would then present a 
case for a new ‘breakthrough’ therapy such as the PCSK9 
inhibitors in terms of costs per life year. If for example, it could 
be demonstrated for a target population, over say a two-year 
timeframe, that the cost-per-life year was lower than a notional 
threshold, the product would be considered for formulary 
listing. Products would be considered on its clinical merits and 
cost implications. This would set the stage for price negotiations 
given the health systems’ own ‘value’ metric. The case for a new 
product would be considered on its merits not as a comparative 
incremental benefit over therapies that may be generically 
priced as shown in the Jena and Shah models. 
 
While the PCSK9 inhibitor models may have a technical appeal 
as an exercise in constructing imaginary treatment scenarios, 
the fact remains that none of them generate evaluable claims. 
They are, although suggestive of possible protocols to drive 
evaluable claims, still imaginary worlds. If we accept the 
standards of normal science, we should put this constructed 
evidence to one side, focusing instead on models and protocols 
that provide the basis for assessing claims in the short term. 
Certainly, we can take on board suggestions that more focused 
treatment strategies in identifying target populations may 
move us away from blanket statements that there need to be 
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substantial price discounts to justify PCSK9 market support. It is 
then up to manufacturers to propose how prices or price 
discounts from wholesale acquisition cost (WAC) may be 
justified in the context of evaluable claims. Evaluable claims 
that might be expressed in terms of willingness-to-pay 
thresholds or more simply in costs per cardiovascular event 
avoided without reference to quality of life.  
 
Even so, there may be concerns by health decision makers that 
accepting ‘indicative’ modeled yet unevaluable claims that 
meet threshold criteria in targeted high-risk or other 
populations, may open the door to a wider utilization. Once 
accepted on formulary, there is no assurance that 
manufacturers would not pursue a marketing or Trojan horse 
pricing strategy that encouraged physicians to prescribe outside 
of the target group. It is, of course, possible that prescribing 
could be ring-fenced by a prior authorization requirement or 
health systems could attempt to monitor prescribing behavior. 
Manufacturers might even agree to restrict advertising and 
physician communications to the target population, agreeing to 
reimburse patients for co-payments and health systems for 
outlays ‘off-target’. The conclusion must be that even if a 
targeted model meets notional outcomes standards, it should 
still be rejected in the absence of any evaluable and replicable 
claims.  
 
This brief review has shown that where the ‘gold standard’ for 
claims rests on the construction of lifetime imaginary worlds to 
support PCK9 inhibitors, model builders have considerable 
latitude in devising their cost-effectiveness case. Options 
abound in the choice of target populations, model structure, 
selection and specification of treatment pathways, choice of 
parameter values (and their distributions in probabilistic 
scenarios), choice of resource units and their costs, selection of 
utilities from the range of instruments, application of 
algorithms for cross-walking items to utility scores and the 
choice of model outcomes.  
 
At the same time, there is always the temptation to construct a 
‘favorable’ imaginary world to support previously established 
post-formulary acceptance pricing strategies. After all, it is 
commonly observed that manufacturers often engage in long-
term annualized price increase strategies so that a ‘market 
entry’ price may be little resemblance to future prices and 
threshold claims. The modeled ‘market entry’ price for the 
imaginary simulation may, indeed, be established simply to 
ensure formulary acceptance by meeting notional cost-per-
QALY thresholds.  As noted, none of the PCSK9 models 
considered here have taken into account possible future price 
increases. This flexibility in pricing assumptions may be a factor 
in the continued support for the construction of imaginary 
worlds in order to gain formulary acceptance.  
 
Mandating a reference case, as health technology assessment 
agencies attempt to do, does little to resolve questions of the 
discretion and direction of model builders. Given NICE as the 
example, the last 18 years have demonstrated how often 
evidence review groups engaged by NICE to review 
manufacturer’s submissions disagree with submitted model 
structures and assumptions and go so far as to put in place 
alternative models (which are then subject to further critique 
by NICE and challenges from the manufacturer). Unless there is 
a way of subjecting model claims to an independent check this 
proliferation of conflicting claims will continue. The check 
suggested here is to put unevaluable claims to one side and 
focus of claims that are evaluable, replicable and capable of 
providing feedback to decision makers in a meaningful 
timeframe. 
 
Choose Your QALY! 
The choice of a QALY measure in cost-utility models has obvious 
implications for cost-per-QALY claims. Different instruments 
yield different utility values to be applied, for example, to the 
various Markov stages through which a hypothetical population 
progresses. This is demonstrated in the models considered 
above where there is no standard for the choice of QALY or any 
suggestion as to how QALY claims in one model may be 
reconciled to claims made by another. Absent a common QALY 
measure or an agreed algorithm for cross-walking QALYs, the 
models are non-comparable in the outcomes claimed and, by 
extension, any claims for price discounting to meet cost-per-
QALY thresholds. The observation that in certain models the 
recommendations for discounting appear to reinforce each 
other is immaterial; if not a red herring. In the absence of 
evaluable and, for example, comparable cost-per-QALY claims, 
no conclusions can be drawn. 
 
Given the range of possible utility measures and the practical 
obstacles to reporting on QALYs in treatment practice it is of 
interest to consider the position of the ACC/AHA task force in 
recommending QALYs as a key outcome that should be 
captured to support transparency in value claims. The task force 
recognized that no national consensus has emerged in the US 
regarding cost-effectiveness, yet the task force hoped that the 
recommended performance standards would be captured by 
study designs incorporating resource utilization and cost 
benefit. The task force also recognized that QALYs may be 
difficult to measure and may be considered controversial in 
economic evaluations. Even so, although not endorsing a 
particular QALY measure or the methodology to capture QALYs, 
they were still seen as representing the preferred metric. 
Unfortunately, sidestepping controversies regarding the choice 
of QALY is difficult to square with their advocacy of willingness-
to-pay thresholds with an indicated range of from $50,000 to 
$150,000 in value recommendations where modeled claims for 
value may embody different measures. To evaluate the quality 
of cost-effectiveness models the force report also points to the 
Quality of Health Economic Studies (QHES) checklist for the 
assessment  of a cost-effectiveness studies 28.  Unfortunately, 
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the checklist does not address the issue of evaluable cost-
effectiveness claims and their replication.  
 
Target Populations, Modeling and Precision Medicine 
Previous commentaries in this series have pointed to the 
potential impact of precision medicine, specifically next 
generation sequencing (NGS), on therapy choice, the design of 
RCTs and establishing evaluable claims 29 30. In the case of the 
PCSK9 inhibitors, as an example, a prior assay evaluation could 
indicate which members of a target population defined on 
empiric grounds are likely to respond to the therapy. The assay 
may suggest that an individual is a probable non-responder and 
that alternative therapies may be more appropriate; even to the 
extent of suggesting alternative therapies to those who are 
probable non-responders to the indicated therapy. If an NGS 
‘filter’ is introduced to guide therapy choices then building 
imaginary claims from empiric randomized trials becomes 
redundant – if not potentially misleading. Rather, health 
systems could require, given the anticipated opportunity costs 
of a mismatching of patients to therapy choice, that an NGS 
assay be integrated as part of treatment guidelines to improve 
the profile of patient outcomes and quality of life. This approach 
may also provide a more robust basis for pricing and discounting 
of the proposed ‘breakthrough’ therapy.  
 
Conclusions: A Rush to Judgement 
Constructing imaginary worlds to support product claims and 
formulary decisions represent an easy way out for those 
involved in health technology assessment. Rather than 
attempting to develop and assess evaluable claims, time and 
resources are spent in justifying the relevance of competing 
constructed imaginary worlds to support and publish 
comparative product claims. The result is that decision makers 
are faced with competing modeled claims justified in terms of 
the reasonableness or otherwise of the model structure and 
assumptions. There is no way of distinguishing the various 
claims in empirical terms. Quite reasonably: why should 
decision makes pay attention to imaginary recommendations 
for formulary acceptance and pricing based upon constructed 
claims that are immune to failure? 
 
It is understandable and, indeed even laudable, that research 
groups should attempt to present evidence and 
recommendations to support formulary decisions and pricing 
policies as soon as products receive marketing approval in their 
target indication. This does not condone, however, the creation 
of modeled or simulated imaginary worlds to support non-
evaluable claims and, in this case of PCSK9 inhibitors, 
constructed recommendations for price discounts. Previous 
commentaries in this series have argued that, rather than 
constructing evidence, manufacturers should commit to 
underwriting protocols to support evaluable and replicable 
claims. These should be based upon short-term models, or 
based entirely on key randomized clinical trials. Formulary 
committees should establish guidelines to support protocols 
and the reporting of outcomes in a meaningful time frame to 
decision makers, physicians and patients. This position has been 
detailed in the Minnesota proposed guidelines for formulary 
submissions (2nd  Ed. December 2016) 31 
 
Unfortunately, there is a long way to go before these standards 
for claims assessment become accepted practice in health 
systems. Rather, technology assessment groups and 
professional groups, such as the AMCP and ISPOR, are 
committed to the construction of imaginary worlds. This lack of 
correspondence to accepted standards in normal science has 
been detailed in previous commentaries. The result is that there 
are all too often, as in the case of the PSCK9 inhibitors, a number 
of models jostling for the attention of health system decision 
makers. This presents formulary committees with the task of 
selecting between imaginary modeled claims to justify product 
placement and pricing decisions. Whether this decision could be 
made more transparent by model builders jockeying for pole 
position in the modeling stakes is a moot point and, as noted in 
the arguments put forward here, actually irrelevant. There 
seems little mileage in allowing formulary committees access to 
simulation models when all they would be able to do would be 
to crank out more scenario-driven unevaluable claims. 
 
The conclusion is that constructing imaginary worlds and 
unevaluable claims is, at least from the perspective or normal 
science, a pointless exercise. This does not mean that groups 
such as ICER should not continue to construct lifetime cost-per-
QALY claims and make recommendations for price discounting. 
After all, if health technology assessment agencies globally are 
prepared to accept unevaluable modeled lifetime claims based 
on a limited evidence base, where there has been a rush to 
judge the pricing strategies of manufacturers, then formulary 
committees in the US could endorse and make clear that they 
subscribe to standards in guidelines such as those put forward 
by the AMCP. Whether these models would be taken seriously 
by other health care decision makers is an open question; a 
decision that is made more problematic when it is pointed out 
that there are competing models making disparate claims.  
 
Needless to say, it is all too easy to point out that a model can 
be challenged and, indeed, that it is quite possible to construct 
alternative scenarios that could be reverse engineered to give 
entirely different outcomes. If we subscribe to untenable 
standards put in place by technology assessment agencies and 
professional groups, one result is that there is now a generation 
of researchers and graduate students who have been taught 
how to model imaginary worlds to generate unevaluable claims; 
meeting relativist standards rather than the standards of 
normal science and adding to the thousands of already 
published yet unevaluable modeled claims in health technology 
assessment.  
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Evidence and recommendations for product placement and 
pricing should be credible, evaluable and replicable. This is not 
the case where these claims are based on the creation of  
imaginary worlds, irrespective of whether or not they are seen 
by the model builder as a sufficient representation of a ‘future 
reality’. While this may be defended on the grounds that there 
is no option when the evidence base at product launch is limited 
and it has to be ‘constructed’, the downside is that it is all too 
easy also to construct alternative imaginary scenarios to justify 
(or otherwise) non-evaluable claims for comparative cost-
effectiveness, budget impact and product pricing that fall below 
(or above) arbitrary willingness-to-pay thresholds. In the 
absence of evaluable and replicable claims, where the model 
captures unknown knowns, known unknowns or unknown 
unknowns, decision makers are asked to take at face value 
recommendations for product placement and pricing. Perhaps 
we should close the wardrobe door on Narnia and focus on 
developing short-term evaluable and replicable claims for cost-
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